JonathanHogan Cabaletta Bio

Jon Hogan is Senior Medical Director at Cabaletta Bio, a Philadelphia-based biotechnology company that is singularly focused on developing curative targeted cellular therapies for autoimmune disease. In this role, he is the clinical lead on Cabaletta\'s CD19 CAR T cell (CABA-201) program for SLE and LN. He is also Adjunct Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Jon completed his nephrology training at Columbia University in New York, as well as a subspecialty fellowship in glomerular diseases at the Columbia Glomerular Center. After staying on faculty at Columbia for one year, he then joined the faculty at the University of Pennsylvania in Philadelphia, where he was the Clinical Director of the Penn Glomerular Center, started the Penn onconephrology program, and was site PI for multiple NIH and industry-sponsored clinical trials.. He spearheaded original research projects and authored numerous peer-reviewed articles during his academic career, and is a co-inventor for a chimeric autoantibody receptor (CAAR) T Cell therapy for PLA2R + membranous nephropathy. Prior to joining Cabaletta Bio, Jon was Clinical Director at Janssen Pharmaceuticals where he was the clinical lead on a clinical trial in lupus nephritis.